JP6838773B2 - 抗インフルエンザウイルスのピリミジニル誘導体 - Google Patents

抗インフルエンザウイルスのピリミジニル誘導体 Download PDF

Info

Publication number
JP6838773B2
JP6838773B2 JP2019512638A JP2019512638A JP6838773B2 JP 6838773 B2 JP6838773 B2 JP 6838773B2 JP 2019512638 A JP2019512638 A JP 2019512638A JP 2019512638 A JP2019512638 A JP 2019512638A JP 6838773 B2 JP6838773 B2 JP 6838773B2
Authority
JP
Japan
Prior art keywords
group
compound
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019512638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529386A5 (cg-RX-API-DMAC7.html
JP2019529386A (ja
Inventor
剣 熊
剣 熊
超峰 龍
超峰 龍
晶晶 王
晶晶 王
小新 陳
小新 陳
新海 陳
新海 陳
程 謝
程 謝
ポン リー,
ポン リー,
宣嘉 彭
宣嘉 彭
健 黎
健 黎
曙輝 陳
曙輝 陳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Raynovent Biotech Co Ltd
Original Assignee
Guangdong Raynovent Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Raynovent Biotech Co Ltd filed Critical Guangdong Raynovent Biotech Co Ltd
Publication of JP2019529386A publication Critical patent/JP2019529386A/ja
Publication of JP2019529386A5 publication Critical patent/JP2019529386A5/ja
Application granted granted Critical
Publication of JP6838773B2 publication Critical patent/JP6838773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019512638A 2016-09-05 2017-09-05 抗インフルエンザウイルスのピリミジニル誘導体 Active JP6838773B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610804101.3 2016-09-05
CN201610804101 2016-09-05
CN201611238759.9 2016-12-28
CN201611238759 2016-12-28
PCT/CN2017/100461 WO2018041263A1 (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Publications (3)

Publication Number Publication Date
JP2019529386A JP2019529386A (ja) 2019-10-17
JP2019529386A5 JP2019529386A5 (cg-RX-API-DMAC7.html) 2020-11-19
JP6838773B2 true JP6838773B2 (ja) 2021-03-03

Family

ID=61300177

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512638A Active JP6838773B2 (ja) 2016-09-05 2017-09-05 抗インフルエンザウイルスのピリミジニル誘導体

Country Status (14)

Country Link
US (4) US11136319B2 (cg-RX-API-DMAC7.html)
EP (1) EP3502112B1 (cg-RX-API-DMAC7.html)
JP (1) JP6838773B2 (cg-RX-API-DMAC7.html)
KR (1) KR102312088B1 (cg-RX-API-DMAC7.html)
CN (3) CN109790159B (cg-RX-API-DMAC7.html)
AU (1) AU2017320088B2 (cg-RX-API-DMAC7.html)
CA (1) CA3035680C (cg-RX-API-DMAC7.html)
DK (1) DK3502112T3 (cg-RX-API-DMAC7.html)
IL (1) IL265166B (cg-RX-API-DMAC7.html)
MX (1) MX394277B (cg-RX-API-DMAC7.html)
RU (1) RU2727772C1 (cg-RX-API-DMAC7.html)
SG (1) SG11201901894TA (cg-RX-API-DMAC7.html)
WO (1) WO2018041263A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201901886B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
MX394277B (es) * 2016-09-05 2025-03-24 Guangdong Raynovent Biotech Co Ltd Derivados de pirimidina contra virus de la influenza
CN108218873B (zh) 2016-12-15 2020-07-07 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
US11098042B2 (en) 2017-01-05 2021-08-24 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
EP3763713A4 (en) * 2018-03-05 2021-11-24 Guangdong Raynovent Biotech Co., Ltd. CRYSTAL FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND THE METHOD FOR MANUFACTURING IT
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
CN114127068B (zh) * 2019-07-22 2024-05-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
WO2021047437A1 (zh) * 2019-09-10 2021-03-18 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
CN111454166B (zh) * 2019-12-30 2021-02-26 广东莱佛士制药技术有限公司 制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
WO2022089261A1 (zh) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法
CN114569562B (zh) * 2020-12-01 2025-07-29 南通诺泰生物医药技术有限公司 一种抗流感病毒的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101903354B1 (ko) 2009-06-17 2018-10-04 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
KR20140014110A (ko) * 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
US20130102600A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX381488B (es) * 2014-08-08 2025-03-12 Janssen Sciences Ireland Uc Indoles para su uso en la infección por el virus de la gripe.
RU2737190C2 (ru) * 2015-12-09 2020-11-25 Саншайн Лейк Фарма Ко., Лтд. Ингибиторы репликации вируса гриппа, способы их применения и использование
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
MX394277B (es) * 2016-09-05 2025-03-24 Guangdong Raynovent Biotech Co Ltd Derivados de pirimidina contra virus de la influenza
EP3763713A4 (en) * 2018-03-05 2021-11-24 Guangdong Raynovent Biotech Co., Ltd. CRYSTAL FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND THE METHOD FOR MANUFACTURING IT
CN114127068B (zh) * 2019-07-22 2024-05-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型

Also Published As

Publication number Publication date
US11725009B2 (en) 2023-08-15
MX394277B (es) 2025-03-24
CA3035680C (en) 2023-05-02
WO2018041263A1 (zh) 2018-03-08
AU2017320088B2 (en) 2020-01-30
KR102312088B1 (ko) 2021-10-14
CN110623958B (zh) 2022-05-17
CN110627784A (zh) 2019-12-31
KR20190056380A (ko) 2019-05-24
IL265166A (en) 2019-05-30
MX2019002541A (es) 2019-07-01
ZA201901886B (en) 2021-01-27
RU2727772C1 (ru) 2020-07-23
US20220135558A1 (en) 2022-05-05
CN110627784B (zh) 2021-09-21
EP3502112A4 (en) 2019-06-26
SG11201901894TA (en) 2019-04-29
US20250250275A1 (en) 2025-08-07
EP3502112A1 (en) 2019-06-26
AU2017320088A1 (en) 2019-04-18
CA3035680A1 (en) 2018-03-08
NZ751964A (en) 2021-02-26
DK3502112T3 (da) 2025-09-22
US20230339943A1 (en) 2023-10-26
US12319692B2 (en) 2025-06-03
US11136319B2 (en) 2021-10-05
JP2019529386A (ja) 2019-10-17
CN109790159B (zh) 2020-01-14
CN109790159A (zh) 2019-05-21
EP3502112B1 (en) 2025-07-02
IL265166B (en) 2021-09-30
BR112019004420A2 (pt) 2019-05-28
US20210032238A1 (en) 2021-02-04
CN110623958A (zh) 2019-12-31

Similar Documents

Publication Publication Date Title
JP6838773B2 (ja) 抗インフルエンザウイルスのピリミジニル誘導体
JP2019529386A5 (cg-RX-API-DMAC7.html)
JP6564473B2 (ja) Janusキナーゼ阻害剤
JP7237010B2 (ja) Hdac6選択的阻害剤およびその製造方法と使用
JP6605157B2 (ja) デゾシンの類似体
KR102547709B1 (ko) 아제티딘 유도체
JP6951418B2 (ja) 抗hcmvウイルス化合物
US20180104220A1 (en) Imidazole compound
HK40003826B (en) Anti-influenza virus pyrimidine derivatives
HK40003826A (en) Anti-influenza virus pyrimidine derivatives
BR112019004420B1 (pt) Composição farmacêutica
RU2772274C2 (ru) Селективные ингибиторы hdac6, способ их получения и их применение
CN121226285A (zh) 一种pde2/4双靶点抑制剂及其制备方法与应用
WO2024061300A1 (en) Inhibitors of trex1 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210201

R150 Certificate of patent or registration of utility model

Ref document number: 6838773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250